Comparing the Efficacy of Latanoprost (0.005%), Bimatoprost (0.03%), Travoprost (0.004%), and Timolol (0.5%) in the Treatment of Primary Open Angle Glaucoma
1
조회
0
다운로드
2
인용
0
참고문헌
키워드
초록
Purpose: To compare the efficacy and safety of latanoprost, bimatoprost, travoprost and timolol in reducing intraocular pressure (IOP) in patients with primary open angle glaucoma. Methods: This was a prospective study conducted at a tertiary-care centre. One hundred and forty patients with newly diagnosed primary open angle glaucoma were randomly assigned to treatment with latanoprost (0.005%), bimatoprost (0.03%), travoprost (0.004%) or timolol gel (0.5%); 35 patients were assigned to each group. All patients were followed for 2, 6, and 12 weeks. The main outcome measure studied was the change in IOP at week 12 from the baseline values. Safety measures included recording of adverse events. Results: The mean IOP reduction from baseline at week 12 was significantly more with bimatoprost (8.8 mmHg, 35.9%) than with latanoprost (7.3 mmHg, 29.9%), travoprost (7.6 mmHg, 30.8%) or timolol (6.7 mmHg, 26.6%) (ANOVA and Student’s t-tests, p < 0.001). Among the prostaglandins studied, bimatoprost produced a maximum reduction in IOP (-2.71; 95% confidence interval [CI], -2.25 to -3.18) followed by travoprost (-1.27; 95% CI, -0.81 to -1.27) and latanoprost (-1.25; 95% CI, -0.79 to -1.71); these values were significant when compared to timolol at week 12 (Bonferroni test, p < 0.001). Latanoprost and travoprost were comparable in their ability to reduce IOP at each patient visit. Ocular adverse-events were found in almost equal proportion in patients treated with bimatoprost (41.3%) and travoprost (41.9%), with a higher incidence of conjunctival hyperemia (24.1%) seen in the bimatoprost group. Timolol produced a significant drop in heart rate (p < 0.001) at week 12 when compared to the baseline measurements. Conclusions: Bimatoprost showed greater efficacy when compared to the other prostaglandins, and timolol was the most efficacious at lowering the IOP. Conjunctional hyperemia was mainly seen with bimatoprost. However, the drug was tolerated well and found to be safe.
Abstract
Purpose: To compare the efficacy and safety of latanoprost, bimatoprost, travoprost and timolol in reducing intraocular pressure (IOP) in patients with primary open angle glaucoma. Methods: This was a prospective study conducted at a tertiary-care centre. One hundred and forty patients with newly diagnosed primary open angle glaucoma were randomly assigned to treatment with latanoprost (0.005%), bimatoprost (0.03%), travoprost (0.004%) or timolol gel (0.5%); 35 patients were assigned to each group. All patients were followed for 2, 6, and 12 weeks. The main outcome measure studied was the change in IOP at week 12 from the baseline values. Safety measures included recording of adverse events. Results: The mean IOP reduction from baseline at week 12 was significantly more with bimatoprost (8.8 mmHg, 35.9%) than with latanoprost (7.3 mmHg, 29.9%), travoprost (7.6 mmHg, 30.8%) or timolol (6.7 mmHg, 26.6%) (ANOVA and Student’s t-tests, p < 0.001). Among the prostaglandins studied, bimatoprost produced a maximum reduction in IOP (-2.71; 95% confidence interval [CI], -2.25 to -3.18) followed by travoprost (-1.27; 95% CI, -0.81 to -1.27) and latanoprost (-1.25; 95% CI, -0.79 to -1.71); these values were significant when compared to timolol at week 12 (Bonferroni test, p < 0.001). Latanoprost and travoprost were comparable in their ability to reduce IOP at each patient visit. Ocular adverse-events were found in almost equal proportion in patients treated with bimatoprost (41.3%) and travoprost (41.9%), with a higher incidence of conjunctival hyperemia (24.1%) seen in the bimatoprost group. Timolol produced a significant drop in heart rate (p < 0.001) at week 12 when compared to the baseline measurements. Conclusions: Bimatoprost showed greater efficacy when compared to the other prostaglandins, and timolol was the most efficacious at lowering the IOP. Conjunctional hyperemia was mainly seen with bimatoprost. However, the drug was tolerated well and found to be safe.
참고문헌 (19)
- Resnikoff S, "Global data on visual impairment in the year 2002", Bull World Health Organ, 82, pp.844~851 (2002)
- Quigley HA, "The number of people with glaucoma worldwide in 2010 and 2020", Br J Ophthalmol, 90, pp.262~267 (2006)
- Ramakrishnan R, "Glaucoma in a rural population of southern India: the Aravind comprehensive eye survey", Ophthalmology, 110, pp.1484~1490 (2003)
- Holmstrom S, "Analytic review of bimatoprost, latanoprost and travoprost in primary open angle glaucoma", Curr Med Res Opin, 21, pp.1875~1883 (2005)
- Stewart WC, "Meta-analysis of 24-hour intraocular pressure studies evaluating the efficacy of glaucoma medicines", Ophthalmolog y, 115, pp.1117~1122 (2008)
- Schenker HI, "Long-term intraocular pressure-lowering efficacy and safety of timolol maleate gel-forming solution 0.5% compared with Timoptic XE 0.5% in a 12-month study", Am J Ophthalmol, 130, pp.145~150 (2000)
- Parrish RK, "A comparison of latanoprost, bimatoprost, and travoprost in patients with elevated intraocular pressure: a 12-week, randomized, masked-evaluator multicenter study", Am J Ophthalmol, 135, pp.688~703 (2003)
- Walters TR, "24-Hour IOP control with once-daily bimatoprost, timolol gel-forming solution, or latanoprost: a 1-month, randomized, comparative clinical trial", Surv Ophthalmol, 49(Suppl 1), pp.S26~S35 (2004)
- Netland PA, "Travoprost compared with latanoprost and timolol in patients with open-angle glaucoma or ocular hypertension", Am J Ophthalmol, 132, pp.472~484 (2001)
- Zhang WY, "Meta-analysis of randomized controlled trials comparing latanoprost with timolol in the treatment of patients with open angle glaucoma or ocular hypertension", Br J Ophthalmol, 85, pp.983~990 (2001)
- Gandolfi S, "Three-month comparison of bimatoprost and latanoprost in patients with glaucoma and ocular hypertension", Adv Ther, 18, pp.110~121 (2001)
- Noecker RS, "A six-month randomized clinical trial comparing the intraocular pressure-lowering efficacy of bimatoprost and latanoprost in patients with ocular hypertension or glaucoma", Am J Ophthalmol, 135, pp.55~63 (2003)
- Sen EM, "A comparison of latanoprost, travoprost and bimatoprost in the treatment of patients with primary open angle glaucoma", Turkiye Klinikleri J Ophthalmol, 15, pp.12~17 (2006)
- Yildirim N, "The effect of latanoprost, bimatoprost, and travoprost on circadian variation of intraocular pressure in patients with open-angle glaucoma", J Glaucoma, 17, pp.36~39 (2008)
- Goldberg I, "Comparison of topical travoprost eye drops given once daily and timolol 0.5% given twice daily in patients with open-angle glaucoma or ocular hypertension", J Glaucoma, 10, pp.414~422 (2001)
- Aptel F, "Efficacy and tolerability of prostaglandin analogs: a meta-analysis of randomized controlled clinical trials", J Glaucoma, 17, pp.667~673 (2008)
- Brandt JD, "Comparison of once- or twice-daily bimatoprost with twice-daily timolol in patients with elevated IOP: a 3-month clinical trial", Ophthalmology, 108, pp.1023~1031 (2001)
- Honrubia F, "Conjunctival hyperaemia with the use of latanoprost versus other prostaglandin analogues in patients with ocular hypertension or glaucoma: a meta-analysis of randomised clinical trials", Br J Ophthalmol, 93, pp.316~321 (2009)
- DuBiner H, "Efficacy and safety of bimatoprost in patients with elevated intraocular pressure:a 30-day comparison with latanoprost", Surv Ophthalmol, 45(Suppl 4), pp.S353~S360 (2001)